Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2014

View Archived Issues

World Parkinson's Day News: recent pathological insights and repurposing efforts

ASP-8273 efficiently induces and maintains tumor growth regression in mutant EGFR NSCLC models

Bristol-Myers Squibb presents first-in-human results for the anti-atherosclerosis agent BMS-962476

Dana-Farber awarded research grant to study cancer vaccine

Mutation in HIBCH gene identified in patient with Leigh syndrome

Novartis presents a novel covalent inhibitor of mutant-selective EGFR for the treatment of NSCLC

PRX-002 enters phase I for Parkinson's disease

Alpha-1-acid glycoprotein investigated as a breast cancer biomarker

Data and safety monitoring board recommends continuation of ixCELL-DCM trial

Biogen Idec and Sobi report topline results from phase III Eloctate trial

Investigator-initiated study begins for BL-8040 in chronic myeloid leukemia

Researchers at Genzyme disclose new GCS inhibitors

Novel BTK inhibitors presented by Roche

Scientists at Roche design novel agents for CNS disorders

Assembly Pharmaceuticals raises funds to advance drugs for HBV

Bristol-Myers Squibb divulges new Notch signaling inhibitors for cancer

Tetra Discovery collaborates with Broad Institute's Stanley Center on schizophrenia

AVEO Oncology and Biodesix partner on development of ficlatuzumab and companion diagnostic test

APEPTICO reports topline results from phase IIa study of AP-301

Xencor receives milestone payment under XmAb antibody product agreement

Ironwood Pharmaceuticals synthesizes novel sGC activators for PAH and other disorders

Neurolixis receives grant to test NLX-101 in animal models of Rett syndrome

DNA gyrase inhibitors show activity against M. kansasii

Pfizer returns Aversion product rights to Acura Pharmaceuticals

FDA accepts Stemline Therapeutics' IND for phase II trial of SL-701 for GBM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...